tirzepatide fda update confirms shortage is still over, gives compounders a grace period White - **UPDATE ON TIRZEPATIDE**

Imatinib, bestatin, roflumilast, palacaparib, thalidomide/pomalidomide and semaglutide outperform the current standard of care by reducing mortality and/or neurological deficits in mice via suppression of neuroinflammation

Proteomic analysis of serum EV from GDM patients revealed significant changes in 78 proteins, primarily involving complement and coagulation cascades, platelet activation, prothrombotic factors, and cholesterol metabolism

But certain symptoms need prompt attention: Severe muscle pain, tenderness, or weakness that limits daily activities Dark or tea colored urine (this can be a sign of rhabdomyolysis, a rare but serious condition involving muscle breakdown) Swelling, redness, or warmth in a specific joint Body aches accompanied by fever or chills Symptoms that worsen with each dose increase and do not improve between doses Rhabdomyolysis is extremely rare, but it has been reported in at least one case linked to tirzepatide use

But the real first scientific breakthrough that happened was in the early 70s